Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response

Overview

Journal J Gastrointest Cancer

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2018 Jul 3

PMID 29961919

Citations 1

Authors

Vineet Govinda Gupta

Ranga Rao Rangaraju

Rajat Saha

Peush Bajpai

Affiliations

Soon will be listed here.

Citing Articles

Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer.

Xu D, Luo Y, Wang P, Li J, Ma L, Huang J Front Oncol. 2023; 13:1148131.

PMID: 37384288 PMC: 10295723. DOI: 10.3389/fonc.2023.1148131.

References

Kim S, Lee J, Lee S, Park S, Jung S, Park Y . Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. Oncotarget. 2016; 7(17):24088-96. PMC: 5029686. DOI: 10.18632/oncotarget.8175. View

Maeda K, Chung Y, Ogawa Y, Takatsuka S, Kang S, Ogawa M . Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996; 77(5):858-63. DOI: 10.1002/(sici)1097-0142(19960301)77:5<858::aid-cncr8>3.0.co;2-a. View

Trump D . Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T,.... Urol Oncol. 2015; 34(5):251. DOI: 10.1016/j.urolonc.2015.03.015. View

Tan A, Dowlati A, Stein M, Jones S, Infante J, Bendell J . Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. Br J Cancer. 2014; 110(11):2647-54. PMC: 4037836. DOI: 10.1038/bjc.2014.233. View

Fuchs C, Tomasek J, Yong C, Dumitru F, Passalacqua R, Goswami C . Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2013; 383(9911):31-39. DOI: 10.1016/S0140-6736(13)61719-5. View

Lopez-Chavez A, Young T, Fages S, Leon L, Schiller J, Dowlati A . Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. J Thorac Oncol. 2012; 7(11):1707-12. DOI: 10.1097/JTO.0b013e318265b500. View

Hamberg P, Verweij J, Sleijfer S . (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010; 15(6):539-47. PMC: 3227994. DOI: 10.1634/theoncologist.2009-0274. View

Shah M . Update on metastatic gastric and esophageal cancers. J Clin Oncol. 2015; 33(16):1760-9. DOI: 10.1200/JCO.2014.60.1799. View

Oza A, Cook A, Pfisterer J, Embleton A, Ledermann J, Pujade-Lauraine E . Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015; 16(8):928-36. PMC: 4648090. DOI: 10.1016/S1470-2045(15)00086-8. View

10.

Burris 3rd H, Dowlati A, Moss R, Infante J, Jones S, Spigel D . Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther. 2012; 11(8):1820-8. DOI: 10.1158/1535-7163.MCT-11-0997. View

11.

Ulahannan S, Brahmer J . Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest. 2011; 29(4):325-37. PMC: 3082199. DOI: 10.3109/07357907.2011.554476. View

12.

du Bois A, Floquet A, Kim J, Rau J, Del Campo J, Friedlander M . Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014; 32(30):3374-82. DOI: 10.1200/JCO.2014.55.7348. View

13.

Saito S, Muneoka Y, Ishikawa T, Akazawa K . Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan. Clin Ther. 2017; 39(12):2380-2388. DOI: 10.1016/j.clinthera.2017.10.017. View

14.

Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26):2473-83. DOI: 10.1056/NEJMoa1104390. View

15.

Shen L, Li J, Xu J, Pan H, Dai G, Qin S . Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2014; 18(1):168-76. PMC: 4544634. DOI: 10.1007/s10120-014-0351-5. View

16.

Wilke H, Muro K, Van Cutsem E, Oh S, Bodoky G, Shimada Y . Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15(11):1224-35. DOI: 10.1016/S1470-2045(14)70420-6. View

17.

Chen L, Oh D, Ryu M, Yeh K, Yeo W, Carlesi R . Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Res Treat. 2017; 49(4):851-868. PMC: 5654167. DOI: 10.4143/crt.2016.176. View

18.

Yu P, Huang L, Cheng G, Yang L, Dai G, Ying J . Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget. 2017; 8(47):82558-82570. PMC: 5669910. DOI: 10.18632/oncotarget.19759. View

19.

Kim S, Shim K, Jung S, Yoo K, Lee J . The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver. 2010; 3(2):88-94. PMC: 2852692. DOI: 10.5009/gnl.2009.3.2.88. View

20.

Ohtsu A, Shah M, Van Cutsem E, Rha S, Sawaki A, Park S . Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011; 29(30):3968-76. DOI: 10.1200/JCO.2011.36.2236. View